Greenville, N.C. — ECU Health Medical Center recently surpassed 100 GammaTile® procedures for patients with brain tumors, marking a significant milestone in advancing access to innovative cancer care across eastern North Carolina. The achievement places ECU Health among a limited number of centers nationwide with this level of experience using GammaTile®, an FDA-approved, surgically targeted radiation therapy designed to improve outcomes for patients with operable brain tumors.
“Reaching 100 GammaTile® procedures is a significant achievement that reflects ECU Health’s commitment to advancing brain tumor care for patients across eastern North Carolina,” said Dr. Stuart Lee, chief of the division of Neurosurgery at ECU Health and medical director of The Gamma Knife Center at ECU Health Medical Center.
“For many of our patients, GammaTile® offers the advantage of receiving surgery and radiation treatment during a single hospitalization, helping reduce barriers to care and ensuring they can access advanced treatment closer to home. There are few centers in the country with this level of experience, and it reflects the expertise of our multidisciplinary team and our commitment to advancing the standard of care for patients with brain tumors.”
With the American Cancer Society estimating more than 24,000 malignant tumors of the brain or spinal cord diagnosed in 2026 across the United States, the need for timely access to advanced treatment options continues to grow.
ECU Health began offering GammaTile® therapy in 2019 and has steadily expanded its use, particularly for patients with metastatic brain tumors requiring surgery. The treatment involves placing small, bioabsorbable collagen tiles embedded with radiation sources directly into the tumor cavity at the time of surgery, allowing for immediate, localized radiation therapy. Unlike traditional approaches, which often require patients to return weeks after surgery for radiation treatment, GammaTile® delivers therapy at the time of tumor removal, eliminating delays and reducing the risk of missed or postponed follow-up care.
“For patients across eastern North Carolina, this milestone means greater access to advanced cancer treatment close to home,” said Jay Briley, president, ECU Health Medical Center. “By bringing these cutting-edge treatments to our region, we can provide the specialized care patients need without requiring them to travel far from their homes and support systems. This achievement reflects ECU Health’s ongoing commitment to innovation and reinforces our role as a regional leader in delivering specialized care.”
In early 2026, ECU Health earned GammaTile® Center of Excellence Program designation from GT Medical Technologies, recognizing the organization’s clinical expertise, patient education and commitment to improving outcomes for patients with operable brain tumors.